Skip to main content
. 2026 Sep 21;18(9):1194. doi: 10.3390/pharmaceutics18091194
MASH Metabolic dysfunction-associated steatohepatitis
MASLD Metabolic dysfunction-associated steatotic liver disease
PK Pharmacokinetics
AUC Area under the plasma concentration–time curve
BrW Brain weight
CL Clearance
GOF Goodness-of-fit
IIV Inter-individual variability
IV Intravenous
MLP Maximum lifespan potential
SA Simple allometry
ROE Rule of exponents
NCA Noncompartmental analysis
OFV Objective function value
VPC Visual predictive check